Schizophrenia Research
Volume 58, Issue 1 , Pages 69-74 , 1 November 2002

Correlation of plasma neurosteroid levels to the severity of negative symptoms in male patients with schizophrenia

  • Yukihiko Shirayama

      Affiliations

    • Corresponding Author InformationCorresponding author. Division of Molecular Psychiatry, Department of Psychiatry, Yale University School of Medicine, Connecticut Mental Health Center, 34 Park Street, New Haven, CT 06508, USA. Tel.: +1-203-974-7743, fax: +1-203-974-7897
    • Department of Neuropsychiatry, Showa University Fujigaoka Hospital, Yokohama, Japan
    • Department of Psychiatry, Kanto Teishin Hospital, Tokyo, Japan
    • ,
  • Kenji Hashimoto

      Affiliations

    • Division of Cortical Function Disorders, National Institute of Neuroscience, NCNP, Tokyo, Japan
    • Present address: Department of Psychiatry, Graduate School of Medicine, Chiba University, Chiba 260-8670, Japan.
    • ,
  • Yoshio Suzuki

      Affiliations

    • Department of Psychiatry, Kanto Teishin Hospital, Tokyo, Japan
    • Present address: Tsurugaoka Hospital, Machida, Tokyo 195-0055, Japan.
    • ,
  • Teruhiko Higuchi

      Affiliations

    • Department of Neuropsychiatry, Showa University Fujigaoka Hospital, Yokohama, Japan
    • Present address: Kohnodai Hospital, NCNP, Ichikawa, Chiba 272-8516, Japan.

Received 18 April 2001 ,Revised 10 September 2001 ,Accepted 13 September 2001.

References 

  1. Andreasen NC. Negative symptoms in schizophrenia: definition and reliability. Arch. Gen. Psychiatry. 1982;139:784–788
  2. Breier A, Buchanan RW. The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients. Life Sci. 1992;51:1527–1534
  3. Breier A, Wolkowitz OM, Doran AR, Bellar S, Picker D. Neurobiological effects of lumbar puncture stress in psychiatric patients and healthy volunteers. Psychiatry Res. 1988;25:187–194
  4. Deis RP, Leguizamon E, Jahn GA. Feedback regulation by progesterone of stress-induced prolactin release in rats. J. Endocrinol. 1989;120:37–43
  5. Del Rio G, Velardo A, Menozzi R, Zizzo G, Tavernari V, Venneri MG, et al. Acute estradiol and progesterone administration reduced cardiovascular and catecholamine responses to mental stress in menopausal women. Neuroendocrinology. 1998;67:269–274
  6. Dewan MJ, Pandurangi AH, Levy BF, Boucher ML, Major LF. Are schizophrenics with abnormal dexamethasone suppression test results a distinct subgroup?. Acta Psychiatr. Scand. 1985;72:274–277
  7. Foster P. Neuroleptic equivalence. J. Pharmacol. 1989;243:431–432
  8. Freeman EW, Purdy RH, Coutifaris C, Rickels K, Paul SM. Anxiolytic metabolites of progesterone: correlation with mood and performance measures following oral progesterone administration to healthy female volunteers. Neuroendocrinology. 1993;58:478–484
  9. Herz M, Fava GA, Molnar G, Edwards L. The dexamethasone suppression test in newly hospitalized schizophrenic patients. Am. J. Psychiatry. 1985;142:127–129
  10. Kudoh A, Kudo T, Ishihara H, Matsuki A. Depressed pituitary-adrenal response to surgical stress in chronic schizophrenic patients. Neuropsychobiology. 1997;36:112–116
  11. Lerer B, Ran A, Blacker M, Silver H, Weller M, Drummer D, et al. Neuroendocrine responses in chronic schizophrenia. Schizophr. Res. 1988;1:405–410
  12. Marx CE, Lieberman JA. Psychoneuroendocrinology of schizophrenia. Psychiatr. Clin. North Am. 1998;21:413–434
  13. Meltzer HY, Lee MA, Jayathilake K. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia. Neuropsychopharmacology. 2001;24:278–290
  14. Mokrani MC, Duval F, Crocq MA, Bailey PE, Macher JP. Multihormonal responses to apomorphine in mental illness. Psychoneuroendocrinology. 1995;20:365–375
  15. Muck-Seler D, Pivac N, Jakovljevic M, Brzovic Z. Platelet serotonin, plasma cortisol, and dexamethasone supression test in schizophrenic patients. Biol. Psychiatry. 1999;45:1433–1439
  16. Munro JG, Hardiker TM, Leonard DP. The dexamethasone suppression test in residual schizophrenia with depression. Am. J. Psychiatry. 1984;141:250–252
  17. Newcomer JW, Faustman WO, Whiteford HA, Moses JA, Csernansky JG. Symptomatology and cognitive impairment associate independently with post-dexamethasone cortisol concentrations in unmedicated schizophrenic patients. Biol. Psychiatry. 1991;29:855–864
  18. Purdy RH, Morrow AL, Moore PH. Stress-induced elevation of γ-aminobutyric acid type A receptor-active steroids in rat brain. Proc. Natl. Acad. Sci. U. S. A. 1991;88:4553–4557
  19. Räsänen P, Hakko H, Visuri S, Paanila J, Kapanen P, Suomela T, et al. Serum testosterone levels, mental disorders and criminal behaviour. Acta Psychiatr. Scand. 1999;99:348–352
  20. Rinieris P, Hatzimanolis J, Markianon M, Stefanis C. Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients. Neuropsychobiology. 1989;22:146–149
  21. Rubinow DR, Schmidt PJ. Androgens, brain, and behavior. Am. J. Psychiatry. 1996;153:974–984
  22. Schultz SK, Andreasen NC. Schizophrenia. Lancet. 1999;353:1425–1430
  23. Sternbach H. Age-associated testosterone decline in men: clinical issues for psychiatry. Am. J. Psychiatry. 1998;155:1310–1318
  24. Tandon R, Mazzara C, DeQuardo J, Craig KA, Meador-Woodruff JH, Goldman R. Dexamethasone suppression test in schizophrenia: relationship to symptomatology, ventricular enlargement, and outcome. Biol. Psychiatry. 1991;29:953–964
  25. Tsuchiya T, Horii I. Differential effects of acute and chronic immobilization stress on plasma testosterone levels in male syrian hamsters. Psychoneuroendocrinology. 1995;20:95–102
  26. Viau V, Meaney MJ. The inhibitory effect of testosterone on hypothalamic-pituitary-adrenal responses to stress is mediated by the medial preoptic area. J. Neurosci. 1996;16:1866–1876
  27. Walder DJ, Walker EF, Lewine RJ. Cognitive functioning, cortisol release, and symptom severity in patients with schizophrenia. Biol. Psychiatry. 2000;48:1121–1132
  28. Walker EF, Diforio D. Schizophrenia: a neural diathesis-stress model. Psychol. Rev. 1997;104:667–685
  29. Yates WR. Testosterone in Psychiatry—risks and benefits. Arch. Gen. Psychiatry. 2000;57:155–156

PII: S0920-9964(01)00367-X

Schizophrenia Research
Volume 58, Issue 1 , Pages 69-74 , 1 November 2002

Article Tools

* Image Usage & Resolution